Esperion’s Cholesterol Drugs Gain Wider FDA Approval for Heart Protection in Europe
Esperion Therapeutics has seen a major boost after its cholesterol-lowering drugs, Nexletol and Nexlizet, gained wider approval. The US Food and Drug Administration expanded their use in March 2024, covering both primary and secondary prevention of heart-related events in Europe. This move has led to rising confidence among investors and medical professionals alike.
The FDA’s decision in March 2024 broadened the scope of Nexletol and Nexlizet, allowing them to be prescribed for preventing cardiovascular events in a wider range of patients. Around the same time, the European Society of Cardiology and European Atherosclerosis Society included bempedoic acid—the active ingredient in both drugs—in their latest treatment guidelines. This recognition suggests growing acceptance of the medication’s benefits in Europe.
The expanded FDA approval and inclusion in European guidelines have strengthened Nexletol and Nexlizet’s position in cardiovascular care in Europe. With long-term market protection and strong revenue projections, Esperion Therapeutics appears well-placed for sustained growth in the coming years.
